Mirati Therapeutics Inc

-0.45 (-0.24%)
Products, Strategic Combinations

Mirati To Join Sanofi On Study Evaluating Adagrasib With SHP2 Inhibitor In KRAS G12C-Mutated Lung Cancer

Published: 10/07/2021 21:34 GMT
Mirati Therapeutics Inc (MRTX) - Mirati Therapeutics to Collaborate With Sanofi on Phase 1/2 Study Evaluating Combination of Adagrasib With a Shp2 Inhibitor in Kras G12c-mutated Lung Cancer.
Mirati Therapeutics Inc - Announced a Non-exclusive Clinical Collaboration Agreement With Sanofi.
Mirati Therapeutics - Agreement With Sanofi to Evaluate Combination of Adagrasib With Sanofi's Investigational Shp2 Inhibitor Sar442720.
Mirati Therapeutics Inc - Under Terms, Sanofi Will Be Responsible for Sponsoring and Operating Phase 1/2 Study.